Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous anifrolumab in pediatric systemic lupus erythematosus
2025-524578-41-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Primary endpoint: Pharmacokinetic parameters after first dose and at Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2025-524578-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524578-41-00.